A Phase 2 interventional study of E2020 in Dementia With Lewy Bodies (DLB), sponsored by Eisai Co., Ltd.. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-09-03.
Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).
239 studies on the registry are indexed under Lewy Body Disease; 88 are open to participants now.
This study's enrollment of 160 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.
Browse Lewy Body Disease studies →Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Drug: E2020
Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
Also known as: Aricept
Change From Baseline in Mini-mental State Examination (MMSE) Total
MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state.
Time frame: Baseline, Week 52, and Week 52 LOCF
Change From Baseline in Neuropsychiatric Inventory (NPI) Score of Psychiatric Symptoms
NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated worse neuropsychiatric outcomes.
Time frame: Baseline, Week 52, and Week 52 LOCF
| Milestone | E2020 |
|---|---|
| Started | 108 |
| Completed | 81 |
| Not completed | 27 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Adverse event | 18 |
| Withdrew: No treatment for 3 weeks | 1 |
| Withdrew: Not eligible | 1 |
| Withdrew: Prohibited concomitant medication | 2 |
| Withdrew: Physician decision | 2 |
MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state.
| Score on a Scale | E2020 | Placebo/E2020 |
|---|---|---|
| Baseline | 20.9 ± 5.1 | 18.6 ± 4.7 |
| Week 52 | 0.3 ± 3.7 | 2 ± 4.4 |
| Week 52 LOCF | 0.2 ± 3.5 | 1.7 ± 4.4 |
NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated worse neuropsychiatric outcomes.
| Score on a Scale | E2020 | Placebo/E2020 |
|---|---|---|
| Baseline | 13.1 ± 16.8 | 17.8 ± 8.2 |
| Week 52 | -1.9 ± 9.8 | -4.1 ± 10.1 |
| Week 52 LOCF | -0.7 ± 11.1 | -4.3 ± 9.7 |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E2020 | — | 8/108 (7.4%) | 53/108 (49.1%) |
| Event | E2020 |
|---|---|
| Compression fractureInjury, poisoning and procedural complications | 3/108 |
| PneumoniaInfections and infestations | 3/108 |
| DehydrationMetabolism and nutrition disorders | 2/108 |
| Psychiatric symptomPsychiatric disorders | 1/108 |
| DizzinessNervous system disorders | 1/108 |
| PoriomaniaPsychiatric disorders | 1/108 |
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/108 |
| Cerebellar infarctionNervous system disorders | 1/108 |
| Bile duct cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/108 |
| Hepatic function abnormalHepatobiliary disorders | 1/108 |
| Event | E2020 |
|---|---|
| Blood creatine phosphokinase increasedInvestigations | 12/108 |
| ContusionInjury, poisoning and procedural complications | 12/108 |
| NasopharyngitisInfections and infestations | 11/108 |
| Blood pressure increasedInvestigations | 11/108 |
| FallInjury, poisoning and procedural complications | 11/108 |
| DiarrhoeaGastrointestinal disorders | 10/108 |
| ParkinsonismNervous system disorders | 8/108 |
| ConstipationGastrointestinal disorders | 8/108 |
| Blood urine presentInvestigations | 7/108 |
| Protein urine presentInvestigations | 7/108 |
| Age, Continuous(Years) | E2020 |
|---|---|
| Mean | 78.9 ± 5.7 |
| Sex: Female, Male(Participants) | E2020 |
|---|---|
| Female | 68 |
| Male | 40 |
| Weight(kg) | E2020 |
|---|---|
| Mean | 49 ± 9.24 |
No study locations are listed for this record.
The record gives a start of Feb 2008, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil